Enclomiphene Citrate Cost in Maine 2026

What Is Enclomiphene Citrate and Why Is It Prescribed?

Enclomiphene citrate is the trans-isomer of clomiphene, and it raises luteinizing hormone (LH) and follicle-stimulating hormone (FSH) by blocking estrogen receptors at the hypothalamus. Unlike exogenous testosterone, it preserves intratesticular testosterone production and keeps sperm parameters intact. Clinicians use it off-label for secondary (hypogonadotropic) hypogonadism in men who want to maintain fertility while correcting low testosterone.

Kim et al. (BJU Int, 2016, N=303) showed that enclomiphene 12.5 mg and 25 mg daily raised serum testosterone to normal range in men with secondary hypogonadism while keeping sperm concentrations significantly higher than in the testosterone gel comparator group [1]. Men on testosterone gel saw sperm concentration fall by roughly 94% from baseline, while enclomiphene-treated men held sperm concentration stable, a difference reaching P<0.001 [1]. That contrast explains why fertility-conscious men in Maine increasingly request enclomiphene over topical testosterone.

The FDA has reviewed enclomiphene under the trade name Androxal, issuing a complete response letter rather than full approval for the secondary hypogonadism indication [2]. Because no FDA-approved finished drug product is currently marketed at retail scale, most dispensing in Maine flows through 503A compounding pharmacies, which operate under a valid patient-specific prescription.

Physiologically, secondary hypogonadism is defined by low serum testosterone alongside low or inappropriately normal LH and FSH. The Endocrine Society's 2018 clinical practice guideline on male hypogonadism recommends confirming the diagnosis with at least two morning total testosterone measurements below the laboratory reference range before initiating any therapy [3]. Enclomiphene fits squarely in the secondary-hypogonadism category because it corrects the upstream signaling deficit rather than bypassing the hypothalamic-pituitary axis entirely.

How Much Does Enclomiphene Citrate Cost in Maine?

Cash-pay cost for compounded enclomiphene in Maine sits at approximately $90 per month through 503A-licensed pharmacies. No standard retail chain price exists because FDA-approved finished product is not widely stocked at Maine CVS, Walgreens, or Hannaford pharmacy locations.

The $90/month figure assumes a typical 25 mg capsule or tablet dispensed as a 30-day supply. Some compounders offer a 90-day supply at a modest per-unit discount, bringing the effective monthly cost closer to $75, 80 when patients pay upfront. Shipping to Maine addresses from out-of-state 503A pharmacies is generally permitted, provided the pharmacy holds the appropriate state licensure.

For comparison, clomiphene citrate (the racemic parent compound) can be obtained at major Maine pharmacies for as little as $15, 30 per month using GoodRx-style discount cards [4]. Clomiphene contains both the cis-zuclomiphene and trans-enclomiphene isomers, making it pharmacologically distinct from pure enclomiphene, but some physicians prescribe it as a lower-cost alternative when fertility outcomes are not the primary concern. Testosterone cypionate injections, the most commonly prescribed TRT form in the United States, cost roughly $30, 80 per month at cash pay depending on dose and pharmacy [5]. Enclomiphene's $90/month price point is therefore competitive with injectable TRT when the fertility-preservation advantage is factored in.

Patients using a telehealth platform may pay a monthly membership or consultation fee on top of the medication cost. That fee typically ranges from $25 to $75 per month depending on the platform, so total out-of-pocket cost in Maine for a telehealth-managed enclomiphene regimen could reach $115, 165 per month all-in.

Does Maine Medicaid Cover Enclomiphene Citrate?

Maine Medicaid (MaineCare) covers enclomiphene citrate for secondary hypogonadism with prior authorization. Coverage is not automatic, and the off-label status of the drug means prescribers must submit clinical documentation supporting medical necessity.

A successful PA submission to MaineCare typically includes: confirmed serum total testosterone below the reference range on two separate morning draws, LH and FSH results showing secondary (not primary) hypogonadism, a prescriber note explaining why exogenous testosterone is not appropriate (for example, active fertility intent), and the specific ICD-10 code for male hypogonadism (E23.0 for hypopituitarism or E29.1 for testicular hypofunction, depending on etiology). The Maine Department of Health and Human Services administers MaineCare and publishes its preferred drug list (PDL) through the state's pharmacy benefit manager [6]. Enclomiphene does not appear on the PDL as a preferred agent, which makes the PA pathway the only covered route.

Denial rates for off-label PA requests vary by plan. If MaineCare denies the initial PA, prescribers may file a clinical exception appeal. The Endocrine Society guideline explicitly states that "testosterone therapy is strongly recommended for men who have classic androgen deficiency syndromes," but notes that fertility preservation represents a valid reason to choose alternative agents [3]. That language supports the appeal argument for enclomiphene when the patient documents fertility goals.

Is Compounded Enclomiphene Citrate Legal in Maine?

Yes. Compounded enclomiphene citrate is legal in Maine when dispensed by a 503A pharmacy operating under a valid patient-specific prescription. Federal law under 21 U.S.C. § 353a (Section 503A of the Federal Food, Drug, and Cosmetic Act) permits state-licensed pharmacies to compound drugs for individual patients, provided the compounded preparation is not a copy of a commercially available FDA-approved product [7]. Because no finished, commercially distributed enclomiphene product is currently on U.S. pharmacy shelves at scale, 503A compounding is legally defensible.

503B outsourcing facilities, which operate under a different FDA oversight framework and may produce larger batch quantities, have faced more regulatory scrutiny regarding enclomiphene. The FDA's guidance on compounding from bulk drug substances lists enclomiphene's status as subject to ongoing evaluation [2]. Patients and prescribers in Maine should confirm their dispensing pharmacy holds a current 503A designation rather than a 503B classification to stay within the clearest legal pathway.

Maine Board of Pharmacy regulations align with federal 503A standards. Pharmacists at Maine 503A facilities must prepare each batch from pharmaceutical-grade API (active pharmaceutical ingredient) with a certificate of analysis confirming identity, potency, and purity. Patients can request that certificate of analysis from their compounding pharmacy before filling a prescription.

Which Insurance Plans Cover Enclomiphene Citrate in Maine?

Private insurance coverage for enclomiphene in Maine is inconsistent and plan-specific. No major Maine commercial insurer lists enclomiphene as a preferred formulary drug in 2026. Coverage, when it exists, requires PA and often a step-therapy requirement showing that clomiphene or another agent was tried first.

Maine's largest commercial plans include Anthem Blue Cross Blue Shield of Maine, Harvard Pilgrim Health Care, and Aetna. Each uses its own formulary and medical-necessity criteria. Patients should call the member services number on their insurance card and ask specifically whether NDC codes for compounded enclomiphene capsules are eligible for reimbursement under the prescription benefit. Compounded medications often fall under a medical benefit rather than a pharmacy benefit, which changes the claims process.

The Affordable Care Act requires most non-grandfathered plans to cover preventive services rated A or B by the U.S. Preventive Services Task Force without cost-sharing, but male hypogonadism treatment is not in that category [8]. Coverage therefore rests entirely on the plan's medical-necessity and formulary policies rather than any federal mandate.

Men enrolled in employer-sponsored high-deductible health plans (HDHPs) paired with a health savings account (HSA) may use HSA funds tax-free to pay for prescribed medications, including compounded enclomiphene, reducing the effective after-tax cost by roughly 22 to 37% depending on their marginal tax rate [9].

Telehealth Prescribing of Enclomiphene in Maine

Telehealth prescribing for enclomiphene is permitted in Maine, and no in-person visit is required to initiate treatment. Maine telehealth law (22 M.R.S.A. § 3173-C) allows licensed Maine physicians, nurse practitioners, and physician assistants to evaluate patients and issue controlled and non-controlled prescriptions via synchronous audio-video encounters [10]. Enclomiphene is not a controlled substance, so the prescribing pathway is straightforward.

A typical telehealth intake for enclomiphene proceeds as follows. The patient completes an online health questionnaire and uploads recent lab results, or the platform orders labs through a local draw site in Maine (LabCorp and Quest Diagnostics both have locations in Portland, Bangor, Lewiston, and Augusta). The clinician reviews total testosterone, LH, FSH, estradiol, complete blood count, and a basic metabolic panel. If results support secondary hypogonadism, the clinician issues an electronic prescription to the patient's chosen 503A pharmacy. Follow-up labs are typically ordered at 6 to 8 weeks to verify testosterone normalization and assess tolerability.

The Ryan Haight Online Pharmacy Consumer Protection Act does not restrict enclomiphene prescribing via telehealth because enclomiphene is not a controlled substance under the DEA schedule [11]. That means no in-person DEA-compliant visit is required, unlike with testosterone injections prescribed through some platforms.

What Are the Cheapest Ways to Get Enclomiphene in Maine?

The most cost-effective route for most Maine patients is a 503A compounding pharmacy with a 90-day supply paid cash, especially when the prescribing consultation happens through a telehealth platform that bundles the consultation fee with the medication cost.

Discount card programs such as GoodRx, RxSaver, and Cost Plus Drugs (Mark Cuban's platform) cover some generic drugs but do not currently list compounded enclomiphene because compounded drugs lack the standard NDC codes these programs rely on [4]. Patients should not expect GoodRx to reduce the $90/month compounded price.

Some telehealth platforms that specialize in men's health offer a bundled monthly subscription that includes the consultation, lab interpretation, and medication shipped directly to a Maine address. These bundles can reduce total cost compared to paying for each service separately. Comparing at least three platforms before committing is worth the time, as pricing varies by roughly $40, 60 per month across providers.

Patients who qualify for MaineCare and receive PA approval pay only their standard Medicaid copay, which for most MaineCare enrollees in 2026 is $3, $4 per prescription fill for preferred drugs and up to $8 for non-preferred drugs, per MaineCare cost-sharing rules [6]. That represents the lowest possible out-of-pocket cost available to Maine residents.

Dosing, Monitoring, and Expected Outcomes

Standard enclomiphene dosing in clinical practice is 12.5 mg or 25 mg orally once daily. Kim et al. demonstrated that 12.5 mg daily produced mean morning testosterone of 412 ng/dL (up from 200 ng/dL at baseline) and 25 mg daily produced mean morning testosterone of 489 ng/dL after 12 weeks in the N=303 trial [1]. Both doses kept sperm concentration above the WHO reference threshold of 16 million/mL [12].

Monitoring labs at baseline, 6 to 8 weeks, and 3 months typically include total testosterone (morning draw), LH, FSH, estradiol, hematocrit, and a lipid panel. Estradiol elevation is possible because enclomiphene raises LH and therefore intratesticular testosterone, some of which aromatizes to estradiol. Clinicians may add a low-dose aromatase inhibitor such as anastrozole 0.5 mg twice weekly if estradiol rises above 40, 50 pg/mL with symptoms, though evidence for routine co-administration is limited [13].

Hematocrit monitoring matters less with enclomiphene than with exogenous testosterone because enclomiphene does not directly stimulate erythropoiesis the way supraphysiologic testosterone does. A 2023 review in the Journal of Clinical Endocrinology and Metabolism noted that selective estrogen receptor modulators (SERMs) used for male hypogonadism carry a more favorable erythrocytosis profile than injectable testosterone [13]. That distinction may matter for Maine patients who donate blood, are at risk for polycythemia, or have cardiovascular comorbidities that make hematocrit elevation risky.

The HealthRX clinical team uses a three-tier decision framework when evaluating Maine men for enclomiphene vs. testosterone replacement. Tier 1 screens for secondary hypogonadism confirmation (two morning total testosterone values below 300 ng/dL with low or normal LH/FSH). Tier 2 assesses fertility intent: active fertility desire at any point in the next 24 months moves the patient toward enclomiphene as first-line. Tier 3 evaluates cost and access: MaineCare-enrolled men with PA approval and active fertility intent represent the strongest candidates for enclomiphene as first-line covered therapy; cash-pay men with no fertility concern may find injectable testosterone more cost-effective at $30, 80/month.

Side Effects and Safety Considerations

Enclomiphene's side effect profile is generally mild. The most commonly reported adverse effects in the Kim et al. trial were headache (8.6%), nausea (4.2%), and visual disturbances (2.1%) at 25 mg daily [1]. Visual disturbances are a known class effect of clomiphene isomers and relate to estrogen receptor blockade in retinal tissue. Patients who report any visual changes should stop the medication and contact their prescriber promptly.

The FDA has not approved enclomiphene for any indication as of early 2026, meaning the prescribing clinician assumes responsibility for monitoring and documentation of the off-label use [2]. Informed consent should document the off-label status, available alternatives, and the patient's understanding of the fertility-preservation rationale.

Long-term safety data beyond 12 months remain limited. A 2023 systematic review in Translational Andrology and Urology analyzed five trials of clomiphene/enclomiphene in male hypogonadism totaling 612 participants and found no significant cardiovascular signals at follow-up durations of up to 12 months, though the authors noted that longer trials are needed [14]. Men with a history of thromboembolic events should discuss risk-benefit with their clinician before starting any SERM.

Comparing Enclomiphene to Clomiphene for Maine Patients on a Budget

Clomiphene citrate is FDA-approved for female infertility and is available as a cheap generic at Maine retail pharmacies. Off-label use in men is common, and the cash price with discount cards can be as low as $15, 20 per month at pharmacies in Portland or Bangor [4]. The trade-off is pharmacological: clomiphene contains roughly 62% zuclomiphene (the cis-isomer), which has a much longer half-life and may accumulate, contributing to estrogenic side effects including mood changes and gynecomastia [15].

Enclomiphene as a pure trans-isomer clears faster and produces a cleaner LH-stimulating signal with less estrogenic residue. For men who tried clomiphene and experienced intolerable estrogenic side effects, switching to pure enclomiphene at $90/month is a reasonable next step even without insurance coverage. The $70/month cost difference over a 6-month trial amounts to $420, which many patients consider acceptable given the side-effect profile difference.

For MaineCare patients who receive PA approval for enclomiphene, that $70/month difference is irrelevant because both drugs would be covered at standard copay rates.

Lab Draw Locations in Maine for Enclomiphene Monitoring

Maine residents can access testosterone and hormone panels at LabCorp patient service centers in Portland (100 Brickhill Ave), South Portland, Bangor, Lewiston, and Auburn. Quest Diagnostics locations in Maine include Portland, Scarborough, and Waterville. Many telehealth platforms that prescribe enclomiphene provide a lab requisition electronically, and results route directly back to the platform's clinical team for review.

The Endocrine Society recommends measuring total testosterone by liquid chromatography-tandem mass spectrometry (LC-MS/MS) rather than immunoassay when values fall near the lower limit of normal, because immunoassay precision is lower in the 200 to 400 ng/dL range [3]. Not all Maine draw sites offer LC-MS/MS by default; patients should request it explicitly or ask their telehealth clinician to specify it on the lab order.

Direct-access lab testing without a physician order is available in Maine through services like Ulta Lab Tests or Walk-In Lab, which can lower the cost of baseline hormone panels to $60, 120 for a standard male hormone panel including total testosterone, LH, FSH, and estradiol [16]. That option suits cash-pay patients who want to know their numbers before their first telehealth consultation.